NewswireToday - Press Release Newswire Distribution Service - Pharma / BioTech / Nutrition https://www.newswiretoday.com/ Recent Pharma / BioTech / Nutrition NewswireToday - PRZOOM Headline News - Visit PressReleasesNewswireDistribution.com Sun, 12 Jul 2026 20:54:16 -0400 Pharma / BioTech / Nutrition rss20 by https://www.newswiretoday.com/ newsfeed_888@newswiretoday.com Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine NewswireToday (newswire) - Thu, 09 Jul 2026 00:00:00 -0400 Paris, Ile-de-France France - Ipsen today announced positive topline results from its Phase III BEOND migraine program evaluating Dysport® (abobotulinumtoxinA) for the prevention of episodic (E-BEOND) and chronic migraine (C-BEOND) in adults - Dysport.com / Ipsen.com https://www.newswiretoday.com/news/186521/ Thu, 09 Jul 2026 00:00:00 -0400 Pharma / BioTech / Nutrition STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development NewswireToday (newswire) - Wed, 08 Jul 2026 00:00:00 -0400 Vancouver, British Columbia Canada - Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development - CCRM.ca / LineaBio.com / Stemcell.com https://www.newswiretoday.com/news/186517/ Wed, 08 Jul 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio NewswireToday (newswire) - Wed, 01 Jul 2026 00:00:00 -0400 Paris, Ile-de-France France - Ipsen and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG - Memo-Therapeutics.com https://www.newswiretoday.com/news/186476/ Wed, 01 Jul 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline NewswireToday (newswire) - Mon, 29 Jun 2026 00:00:00 -0400 Paris, Ile-de-France France - Ipsen and Kartos Therapeutics, announced today they have entered into a definitive merger agreement under which Ipsen has agreed to acquire Kartos Therapeutics - KartosThera.com / Ipsen.com https://www.newswiretoday.com/news/186459/ Mon, 29 Jun 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement NewswireToday (newswire) - Thu, 11 Jun 2026 00:00:00 -0400 Osaka, Japan - VELEXBRU was designated as an orphan drug for the indication of central nervous system involvement of malignant lymphoma in patients with inadequate response to existing therapies - ONO-Pharma.com https://www.newswiretoday.com/news/186363/ Thu, 11 Jun 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con NewswireToday (newswire) - Thu, 28 May 2026 00:00:00 -0400 Osaka, Japan - Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC) - ONO-Pharma.com https://www.newswiretoday.com/news/186288/ Thu, 28 May 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity NewswireToday (newswire) - Wed, 20 May 2026 00:00:00 -0400 Paris, Île-de-France France - The trial showed that patients treated with Dysport had a non-inferior safety profile to Botox and achieved longer-lasting symptom control (based on a pre-specified 80% confidence interval)1 - Dysport.com / Botox.com / Ipsen.com https://www.newswiretoday.com/news/186240/ Wed, 20 May 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium NewswireToday (newswire) - Thu, 14 May 2026 00:00:00 -0400 Paris, Île-de-France France - Ipsen announced today the presentation of the Phase II LANTIC trial for the first aesthetic glabellar lines indication with corabotase, a custom-designed molecule recognized as the first in a newly designated class at the SCALE 2026 symposium on May 16 https://www.newswiretoday.com/news/186211/ Thu, 14 May 2026 00:00:00 -0400 Pharma / BioTech / Nutrition SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure NewswireToday (newswire) - Tue, 28 Apr 2026 00:00:00 -0400 Mainz, Germany - SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has announced the development of cartriQ® BioPure, a new sterile glass cartridge - SCHOTT-Pharma.com https://www.newswiretoday.com/news/186118/ Tue, 28 Apr 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma NewswireToday (newswire) - Wed, 22 Apr 2026 00:00:00 -0400 Paris, Île-de-France France - Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration - Ipsen.com https://www.newswiretoday.com/news/186088/ Wed, 22 Apr 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan NewswireToday (newswire) - Thu, 26 Mar 2026 00:00:00 -0400 Osaka, Japan - Ono Pharmaceutical Co., Ltd announced that Ono submitted an application for the manufacturing and marketing approval of ripretinib (DCC-2618), developed by Deciphera Pharmaceuticals, Inc. - Deciphera.com / ONO-Pharma.com https://www.newswiretoday.com/news/185930/ Thu, 26 Mar 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition NewswireToday (newswire) - Wed, 25 Mar 2026 00:00:00 -0400 San Antonio, TX United States - The company is acknowledged for its scalable technology platform, application diversity, and customer-centered commercialization driving multi-industry adoption - LocusFS.com https://www.newswiretoday.com/news/185923/ Wed, 25 Mar 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR NewswireToday (newswire) - Wed, 18 Mar 2026 00:00:00 -0400 Paris, Île-de-France France - Ipsen announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress - AACR.org / Ipsen.com https://www.newswiretoday.com/news/185870/ Wed, 18 Mar 2026 00:00:00 -0400 Pharma / BioTech / Nutrition Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology NewswireToday (newswire) - Tue, 03 Mar 2026 00:00:00 -0500 Osaka, Japan - Ono Pharmaceutical Co., Ltd announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics Congruencetx.com / ONO-Pharma.com https://www.newswiretoday.com/news/185763/ Tue, 03 Mar 2026 00:00:00 -0500 Pharma / BioTech / Nutrition Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment NewswireToday (newswire) - Mon, 02 Mar 2026 00:00:00 -0500 Osaka, Japan - Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment to Daito Pharmaceutical Co., Ltd - Daitonet.co.jp / ONO-Pharma.com https://www.newswiretoday.com/news/185750/ Mon, 02 Mar 2026 00:00:00 -0500 Pharma / BioTech / Nutrition